Amgen biosimilar debut boosted by UnitedHealthcare coverage switch

UnitedHealthcare, the nation's largest insurer, will preferentially cover lower-cost biosimilar versions of Roche's top-selling cancer drugs Herceptin and Avastin beginning Oct. 1, giving a boost to Amgen's efforts to steal away market share.